Prostate Cancer Risk Calculator

Clinical Tool — Dr. Muhammad Khalid

Based on the 7 most evidence-supported risk modifiers. Calculates your risk category and recommends the appropriate screening pathway — the same assessment framework used in urological practice.

This tool estimates relative risk category only. It is not a diagnostic test and does not replace clinical assessment or a PSA blood test.

Step 1 — Demographics

Your Age

Ethnicity

Step 2 — Family History

First-degree relatives with prostate cancer?

None

Father or brother diagnosed age 65+

Father or brother diagnosed before age 65

Two or more first-degree relatives

Any BRCA gene mutations in the family?

No / Not tested

BRCA1 in family

BRCA2 in family

BRCA2 mutations are associated with significantly more aggressive prostate cancer and early onset. BRCA1 confers a smaller increase in risk.

Step 3 — PSA History

Do you have a known PSA value?

No — never tested

Yes — within normal range

Yes — grey zone (4–10 ng/mL)

Yes — elevated (> 10 ng/mL)

Rising trend on serial tests

Have you had a digital rectal examination (DRE)?

No DRE performed

DRE — normal (smooth/symmetrical)

DRE — abnormal (nodule/firmness)

Step 4 — Symptoms

Do you have any urinary symptoms?

No urinary symptoms

Weak stream, urgency, or nocturia

Visible blood in urine

Bone pain + urinary symptoms

Risk Assessment Result

—

🛡️ Protect Yourself: Request an MRI

If your results indicate a high risk, do not let a doctor rush you into a blind prostate biopsy. Current European Association of Urology (EAU) guidelines strongly recommend a Multiparametric MRI (mpMRI) first. Print this risk profile and bring it to your urologist to discuss a targeted MRI approach.

Your Risk Factor Breakdown

Recommended Clinical Pathway

A note on overdiagnosis — what a high-risk result does and does not mean

A higher risk category means you are more likely to benefit from structured screening — not that you have cancer. Approximately 50% of men over 50 have microscopic low-grade prostate cancer at autopsy that would never have caused harm. Modern screening aims to find clinically significant cancers early while avoiding unnecessary investigation of harmless ones. MRI before biopsy reduces unnecessary biopsies by 28% and is the cornerstone of targeted screening.

Dr. Muhammad Khalid

MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · IMC #539472 — Risk factors from EAU Guidelines 2024, Rebbeck TR (2013), and Bruner DW (2003).

This calculator estimates relative risk category only and does not constitute a medical diagnosis. Prostate cancer diagnosis requires PSA testing, clinical examination, and where indicated, MRI and biopsy. Always discuss your screening plan with a urologist or GP.

Does high risk mean I have prostate cancer?

No. This calculator estimates your relative risk of developing prostate cancer compared to the average population, based on known risk modifiers. It does not detect cancer. A high-risk result means more vigilant screening is appropriate — it does not mean cancer is present. Prostate cancer is confirmed only by biopsy after appropriate clinical workup. See the age-by-age screening guide →

What happens if my PSA is in the grey zone (4–10)?

In the grey zone, only approximately 25% of biopsies find cancer. Modern practice does not jump straight to biopsy from a grey-zone PSA. Instead: repeat the PSA 4–6 weeks later; measure free-to-total PSA ratio; and perform a multiparametric MRI before biopsy. Read the full grey zone PSA guide →